SCHEMBL23830207

SCHEMBL23830207

CCc1nccn1Cc1cnc(N2CC3CC3C2)cc1C

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
BTK Q06187 5/20 0.41
KCNH2 Q12809 8/20 0.38
ALDH1A1 P00352 1/20 0.37
ADRA2C P18825 1/20 0.33
KMT2A Q03164 1/20 0.32
ALPG P10696 2/20 0.31
PLAA Q9Y263 1/20 0.31
ALPL P05186 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23830270 0.87 KCNH2 (0.41) BTKKCNH2ALDH1A1
SCHEMBL21713125 0.79 KLKB1 (0.45) ALDH1A1
SCHEMBL23830226 0.77 ALDH1A1 (0.37) KCNH2ALDH1A1
SCHEMBL23830205 0.77 KCNH2 (0.38) KCNH2ALDH1A1
SCHEMBL23830196 0.76 ALDH1A1 (0.36) KCNH2ALDH1A1
SCHEMBL23830256 0.76 KCNH2 (0.41) KCNH2ALDH1A1
SCHEMBL23830186 0.76 BTK (0.44) BTK
SCHEMBL18795060 0.74 BTK (0.41) BTKALDH1A1
SCHEMBL18794995 0.74 BTK (0.39) BTKALDH1A1
SCHEMBL23830209 0.74 ALDH1A1 (0.35) KCNH2ALDH1A1ALPGPLAAALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-03-07 US disclosed
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2024-01-04 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 BTK 1516/4885KCNH2 782/4885ALDH1A1 1223/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 BTK 1516/4885KCNH2 782/4885ALDH1A1 1223/4885
US-20240002363-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 BTK 1516/4885KCNH2 782/4885ALDH1A1 1223/4885
US-20240076286-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 BTK 1516/4885KCNH2 782/4885ALDH1A1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.